Evidence map›Paper›PMID 30607675›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.

Erin McKenzie, Pearl Zaki, Srinivas Raman, Robert Olson, Thomas McFarlane, Carlo DeAngelis, Stephanie Chan, William Pidduck, Yasmeen Razvi, Ahmad Bushehri and 1 more

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. SEOM clinical guideline emesis (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Guideline
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Erin McKenzieSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Pearl ZakiSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Srinivas RamanSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Robert OlsonDepartment of Radiation Oncology, BC Cancer Centre for the North, University of Northern British Columbia, University of British Columbia, Vancouver, BC, Canada.
Thomas McFarlaneSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Carlo DeAngelisSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Stephanie ChanSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
William PidduckSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Yasmeen RazviSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Ahmad BushehriSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Edward ChowSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. Edward.Chow@sunnybrook.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadiation-induced nausea and vomiting (RINV) can affect 50-80% of patients undergoing radiotherapy and negatively impacts quality of life. This review aimed to compare the most recent RINV antiemetic guidelines produced by the Multinational Association for Supportive Care in Cancer (MASCC), the European Society of Clinical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). Future improvements to the guidelines and the need for further research in RINV were also discussed.

methodsAntiemetic guidelines produced by MASCC/ESMO, ASCO, and NCCN were examined to identify similarities, differences, and inadequacies within the guidelines.

resultsAreas of dissension within the guidelines include the addition of dexamethasone to moderate-risk antiemetic regimens, the prophylactic treatment of RINV in the low-risk categories, and the appropriate treatment for breakthrough emesis. The guidelines are in accordance that high-risk radiotherapy regimens should be treated prophylactically with a serotonin receptor antagonist and for those undergoing concurrent chemotherapy and radiotherapy, antiemetic treatment should be prescribed according to the emetic risk associated with their respective chemotherapy regimen. Low- and minimal-risk recommendations are based on low-level evidence and informal consensus.

conclusionRINV is a frequent and distressing side effect of radiotherapy and requires further research to establish effective antiemetic guidelines and ensure optimal treatment outcomes.

Indexed as

Practice Guidelines as TopicAntiemeticsConsensusDexamethasoneEmeticsHumansNauseaNeoplasmsQuality of LifeRadiotherapyResearchRisk FactorsSerotonin AntagonistsVomitingAntiemeticsDexamethasoneEmeticsSerotonin AntagonistsAntiemetic guidelinesAntiemeticsNausea and vomitingRadiation oncology

Identifiers

PMID30607675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.